Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2025 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
August 07, 2025 13:08 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events...
June 03, 2025 09:15 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain...
May 21, 2025 10:00 ET | Source: SPR Therapeutics, Inc.

SPRINT® PNS Meets Primary Endpoint of Reduction in Head Pain in First Publication of Multicenter Prospective MONARCH™ Study

SPRINT® PNS meets the primary endpoint of reduction in head pain in the first publication of multicenter prospective MONARCH™ Study.
May 08, 2025 09:00 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study...
May 08, 2025 09:00 ET | Source: Truveta

Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers

BELLEVUE, Wash., May 08, 2025 (GLOBE NEWSWIRE) -- Today, Truveta announced a new era in cancer research with more than 7 million oncology patient journeys spanning more than 100 cancer types,...
April 29, 2025 09:00 ET | Source: SPR Therapeutics, Inc.

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

SPR announces publication of four-year follow-up data demonstrating significant and sustained low back pain relief following SPRINT PNS treatment.
April 03, 2025 09:00 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain...
March 31, 2025 15:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected...
March 18, 2025 08:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class,...